Skip to Main Content

Program

Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition

PROGRAM
All Times are EST
Program is subject to change

Friday, February 10, 2023

7:50 am Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
  Session I: Non-Exudative AMD
Moderators: Philip J. Rosenfeld, MD, PhD, Giovanni Gregori, PhD, and Zohar Yehoshua, MD, MHA
Panelists: Gregory S. Hageman, PhD, Giovanni Staurenghi, MD, FARVO, FEBO, Christine A. Curcio, FARVO, Lawrence Singerman, MD, Aaron Y. Lee, MD, MSCI, R. Theodore Smith, MD, Mengxi Shen, MD, Justis P. Ehlers, MD, and Baruch D. Kuppermann, MD, PhD
8:00 Age-Related Macular Degeneration: A Tale of Two Biologies
Gregory S. Hageman PhD

8:10 High Resolution OCT of AMD
Giovanni Staurenghi, MD, FARVO, FEBO

8:20 Imaging and Plasma Measures of Xanthophyll Carotenoids in Early Stages of AMD: Elucidating Lutein and Zeaxanthin Bioavailability in the ALSTAR2 Baseline Cohort
Christine A. Curcio, PhD, FARVO

8:30 Short Form of the National Eye Institute Visual Function Questionnaire-25 {NEI VFQ-25}: The VFQ-7
Lawrence Singerman, MD
8:40 Deep Learning Techniques for AMD Biomarkers
Aaron Y. Lee, MD, MSCI
8:50 Subretinal Drusenoid Deposits are Markers for Co-existent High-risk Vascular Diseases
R. Theodore Smith, MD
9:00 Correlations Between Central CC Flow Impairment and Cone Visual Acuity Measurements
Mengxi Shen, MD

9:10 Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint
Justis P. Ehlers, MD

9:20 Reversing Vision Loss in Dry AMD: Matching Mechanism with the Right Patient Population and Stage of Disease
Baruch D. Kuppermann, MD, PhD

  Session II: Predicting Disease Progression in Non-Exudative AMD
Moderators: Jaclyn L. Kovach, MD, Sander R. Dubovy, MD, and Philip J. Rosenfeld, MD, PhD
Panelists: Frank G. Holz, FEBO, FARVO, David Sarraf, MD, Ruikang Wang, PhD, Philip J. Rosenfeld, MD, PhD, Pearse A. Keane, MD, MSc, FRCOphth MRCSI, Emily Y. Chew, MD, and Gemmy Cheung MBBS, FRCOphth, FAMS, MCI
9:30 MACUSTAR Study in Intermediate AMD: Novel Findings
Frank G. Holz, FEBO, FARVO

9:40 Progression of iRORA to cRORA: Challenges in Implementation into Clinical Trials of AMD
David Sarraf, MD

9:50 Automated Algorithms to Quantify Geographic Atrophy and Pigment Burden in AMD
Ruikang Wang, PhD

10:00 The Onset and Progression of Persistent Hypertransmission Defects: A Novel Clinical Trial Endpoint for Studying iAMD
Philip J. Rosenfeld, MD, PhD

10:10 Deep learning in Geographic Atrophy - the Impending Need for AI-enabled Therapeutics
Pearse A. Keane, MD, MSc, FROphth, MRCSI

10:20 The Update of AREDS/AREDS2 on GA Progression and the Role of Reticular Pseudodrusen in AMD Progression
Emily Y. Chew, MD

10:30 Macular Atrophy Phenotypes and Progression Rates in Asians Compared to Non-Asians
Gemmy Cheung MBBS, FRCOphth, FAMS, MCI

  Session III: Therapies for Non-Exudative AMD
Moderators: Ninel Z. Gregori, MD, Philip J. Rosenfeld, MD, PhD, and Raquel Goldhardt, MD, FACS
Panelists: Pedro Lylyk, MD, Amir H. Kashani, MD, PhD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Glenn J. Jaffe, MD, and Peter K. Kaiser, MD
10:40 Intracranial Ophthalmic Angioplasty (IOA): Safety and Preliminary Results, a Better Way to Improve Retinal and Choroidal Perfusion
Pedro Lylyk, MD

10:50 Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy (GA) due to Age-Related Macular Degeneration
Jeffrey S. Heier, MD

11:00 Preliminary Results of a Phase 1/2a Study Using Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelium for Treatment of Advanced Dry Age Related Macular Degeneration with Geographic Atrophy
Amir H. Kashani, MD, PhD

11:10 Results from the Phase II CATALINA Study Evaluating NGM621 for the Treatment of Geographic Atrophy
Arshad M. Khanani, MD, MA

11:20 GATHER1/GATHER2: Comparison of Trial Design and Baseline Patient Populations Influencing Lesion Growth
David Eichenbaum, MD

11:30 C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy: Efficacy Results from the Phase 3 GATHER2 Trial
David R. Lally, MD, FASRS

11:40 Foveal Invasion in GATHER2
Glenn J. Jaffe, MD

11:50 Safety of the Phase 2/3 Gather1 and Gather2 Studies
Peter K. Kaiser, MD

  Session IV: Pegcetacoplan Results for the Treatment of GA: Derby and Oaks Trials
Moderators: Jorge Fortun, MD, Jayanth Sridhar, MD, and Philip J. Rosenfeld, MD, PhD
Panelists: Eleonora M. Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, and Nadia K. Waheed, MD, MPH
12:00 pm 2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Baseline Characteristics and Efficacy
Eleonora M. Lad, MD, PhD

12:10 2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Safety and Exudative Changes
Rishi Singh, MD

12:20 Analytical Strategies for Microperimetry in GA trials: The Oaks Trial Experience
Nadia K. Waheed, MD, MPH

12:30 A Deeper Dive into the 24-Month Results of Derby and Oaks Trials
Jeffrey S. Heier, MD

12:40 Panel Discussion: Derby and Oaks Trials
12:50 Session V
Panel Discussion on Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD

Moderators: Philip J. Rosenfeld MD, PhD
Panelists: SriniVas R. Sadda, MD, Frank G. Holz, FEBO, FARVO, Emily Y. Chew, MD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Peter K. Kaiser, MD, Eleonora Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, Lawrence Singerman, MD, Giovanni Staurenghi, MD, and Nadia K. Waheed, MD, MPH
  Session VI: Exudative AMD
Moderators: Luis J. Haddock, MD, Maura Di Nicola, MD, and Thomas A. Albini, MD
Panelists: Richard F. Spaide, MD, SriniVas R. Sadda, MD, K. Bailey Freund, MD, Jean-Francois Korobelnik MD, PhD, Omer Trivizki, MD, MBA, Ursula Schmidt-Erfurth, MD, Anat Loewenstein, MD, Daniel F. Martin, MD, Nancy Holekamp, MD, Usha Chakravarthy, MD, and Giuseppe Querques, MD
1:20 Inflammatory Cell Involvement in Neovascular Age-Related Macular Degeneration
Richard F. Spaide, MD

1:30 OCT Risk Factors for Development of Macular Neovascularization
SriniVas R. Sadda, MD

1:40 Deep Learning for Automatic Prediction of Early Activation of Treatment-naive Quiescent MNV
Giuseppe Querques, MD

1:50 Deep Retinal Age-Related Microvascular Anomalies (DRAMA): A Mimic or Precursor of Intraretinal Neovascularization?
K. Bailey Freund, MD

2:00 Exudation Assessment on SD-OCT in Wet AMD: B-Scan or Mapping?
Jean-Francois Korobelnik MD, PhD

2:10 Remote Monitoring of Exudative AMD Patients using Macular Thickness Measurements and Optimal Change Thresholding
Omer Trivizki, MD, MBA

2:20 Automated Quantification of Retinal Fluid in Real-World Disease Management
Ursula Schmidt-Erfurth, MD

2:30 AI-Derived Fluid Dynamics in Exudative Retinal Diseases
Anat Loewenstein, MD

2:40 Home OCT and its Potential Role in the Management of Neovascular AMD
Daniel F. Martin, MD

2:50 Home OCT Guided Anti-VEGF Therapy in Patients with nAMD – First Longitudinal Study Results
Nancy Holekamp, MD

3:00 Does Atrophy Precede or Follow Outer Retinal Fibrosis in Treated Neovascular AMD
Usha Chakravarthy, MD

3:10 Adjourn until Saturday, Feb. 11th at 8:00 am

Saturday, February 11, 2023

7:50 am Welcome and Overview
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
  Session VII: Emerging and Current Therapies for Exudative AMD
Moderators: Janet L. Davis, MD, Thomas A. Albini, MD, and Nicolas A. Yannuzzi, MD
Panelists: Tong Li, MD, PhD, Andrew A. Moshfeghi, MD, MBA, Xiaodong Sun, MD, PhD, Charles C. Wykoff, MD, PhD, Justis P. Ehlers, MD, Allen C. Ho, MD, Mark R. Barakat, MD, David M. Brown, MD, FACS, Carl D. Regillo, MD, Robyn Guymer, MBBS, PhD, and Seung-Young Yu, MD
8:00 Update on a Hydrogel-Based Intravitreal Axitinib Intravitreal Implant (OTX-TKI) for the Treatment of Neovascular AMD
Andrew A. Moshfeghi, MD, MBA
8:10 Primary Endpoint Results of a Phase II study of Efdamrofusp Alfa: A Bispecific Fusion Protein Targeting VEGF and Complement in Patients with nAMD: Multicentre, Randomized,Active Controlled Trial
Xiaodong Sun, MD, PhD
8:20 LX102 Gene Therapy for Neovascular AMD
Tong Li, MD, PhD
8:30 Intravitreal ADVM-022 Gene Therapy for Wet AMD: Overview of 2-Year Results with Detailed Analysis of Fluid Volatility and Outer Retinal Integrity
Justis P. Ehlers, MD
8:40 An Update on Subretinal RGX-314 Gene Therapy in nAMD
Charles C. Wykoff, MD, PhD

8:50 Long-Term Follow-Up of Durable Subretinal RGX-314 Gene Therapy for Exudative AMD
Allen C. Ho, MD

9:00 Suprachoroidal Therapy for Neovascular AMD
Mark R. Barakat, MD

9:10 Efficacy and Safety of High-Dose (8.0 mg) Aflibercept of Treatment for Wet AMD: 48-Week Results from PULSAR
David M. Brown, MD, FACS

9:20 Talon Phase 3b Study Results: Brolucizumab vs. Aflibercept in a Matched Treat-and-Extend Superiority Study for Neovascular AMD
Carl D. Regillo, MD

9:30 VOYAGER: An Innovative, Global, Observational Study to Gain Real-World Insights into the Long-term Utilisation of Faricimab and the Port Delivery System with Ranibizumab for the Treatment of nAMD and DME
Robyn Guymer, MBBS, PhD

9:40 Three-Year Clinical Outcomes of Polypoidal Choroidal Vasculopathy Based on Swept-Source OCT Angiography
Seung-Young Yu, MD

  Session VIII: Diabetic Retinopathy-Imaging and Treatment
Moderators: Justin H. Townsend, MD, Harry W. Flynn, Jr., MD, and Basil Williams, MD
Panelists: James G. Fujimoto, PhD, Toshinori Murata, MD, PhD, Peter K. Kaiser, MD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun MD, and Jayanth Sridhar, MD
9:50 OCT Angiography in Diabetic Retinopathy
Harry W. Flynn, Jr., MD

10:00 Advances in Ultrahigh Speed SS-OCT Angiography for Assessing Retinal Blood Flow
James G. Fujimoto, PhD

10:10 The Balance Between Leakage and Drainage in Macular Edema
Toshinori Murata, MD, PhD

10:20 Efficacy and Safety Data for APX3330, a Novel Oral Drug Candidate for DR/DME from the ZETA-1 Phase 2b Trial
Peter K. Kaiser, MD

10:30 Results of the Phase 2 BEHOLD Trial of UBX1325, A Novel Senolytic Agent for Diabetic Macular Edema
Robert Bhisitkul, MD, PhD

10:40 Suprachoroidal Therapy for Diabetic Retinopathy
Peter A. Campochiaro, MD

10:50 Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial
Arshad M. Khanani, MD, MA

11:00 Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Retinopathy: Primary Analysis Results of the Phase 3 Pavilion Trial
Dante Pieramici, MD

11:10 Efficacy and Safety of High-dose (8 mg) Aflibercept for Treatment of DME: 48-Week Results from PHOTON
David S. Boyer, MD

11:20 Results of DRCR Retina Network Protocol AC
Jennifer Sun, MD

11:30 Changes in Prescribing Trends of Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists with Initial Publication of DRCR.net
Jayanth Sridhar, MD

  Session IX: Faricimab in Retinal Vacular Diseases
Moderators: Harry W. Flynn, Jr., MD, Philip J. Rosenfeld, MD, PhD, and William E. Smiddy, MD
Panelists: Karl G. Csaky, MD, PhD, Caroline Baumal, MD, Ramin Tadayoni, MD, PhD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun, MD, Jayanth Sridhar, MD, and Justin H. Townsend, MD
11:40 Ang2/VEGF Biology and Intraocular Suppression Following Intravitreal Administration of Faricimab
Karl G. Csaky, MD, PhD

11:50 Faricimab in RVO - Results from the BALATON and COMINO Phase 3 Studies
Ramin Tadayoni, MD, PhD

12:00 pm Faricimab in nAMD and DME - Latest Updates
Caroline Baumal, MD

12:10 Panel Discussion: Faricimab in Retinal Vascular Diseases
  Session X: Retinal Vascular Diseases and Uveitis
Moderators: Thomas A. Albini MD, Stephen G. Schwartz, MD, MBA, and Zelia Maria Correa, MD, PhD
Panelists: Darius M. Moshfeghi, MD, Michael S. Ip, MD, Diana V. Do, MD, Martin Friedlander, MD, PhD, Thomas A. Albini, MD, Lawrence A. Yannuzzi, MD, Steven Yeh, MD, and Sunil K. Srivastava, MD
12:20 Avascular Retina as the Risk Factor for Failure in BEAT ROP and anti-VEGF Clinical Trials
Darius M. Moshfeghi, MD

12:30 Efficacy and Safety of Intravitreal Aflibercept versus Laser Photocoagulation for ROP: Results from the Phase 3 BUTTERFLEYE Trial
Darius M. Moshfeghi, MD

12:40 Treatment Outcomes with Anti-VEGF Therapy for CRVO and BRVO: An Analysis of the Vestrum Database
Michael S. Ip, MD

12:50 Update on KSI-301 and the BEACON Phase III Pivotal Study for Retinal Vein Occlusion
Diana V. Do, MD

1:00 Results of the Phase 3 MacTel2 CNTF Trial
Martin Friedlander, MD, PhD

1:10 Diagnostic Testing in Uveitis
Thomas A. Albini, MD

1:20 Acute Zonal Occul Outer Retinopathy (AZOOR): Relentless Progression
Lawrence A. Yannuzzi, MD

1:30 Integrated Analysis of Phase 3 Clinical Trials on Suprachoroidal Triamcinolone Acetonide for Macular Edema Due to Noninfectious Uveitis: From Evidence to Clinical Practice
Steven Yeh, MD

1:40 Inflammatory Complications of Gene Therapy
Sunil K. Srivastava, MD

  Session XI: Inherited Retinal Degenerations
Moderators: Philip J. Rosenfeld MD PhD, Byron L. Lam MD, and Harry W. Flynn, Jr., MD
Panelists: Carel B. Hoyng, MD, Quan Dong Nguyen, MD, MSc, and Byron L. Lam, MD
1:50 Stargardt Disease, Phenotyping, and Towards Clinical Trials
Carel B. Hoyng, MD

2:00 Tinlarebant (LBS-008) for Stargardt Disease: The Story Continues
Quan Dong Nguyen, MD, MSc

2:10 Treatments and Clinical Trials for Inherited Retinal Disease
Byron L. Lam, MD

2:20 Post-Program Test and Closing Remarks